novo nordisk patent semaglutide Ozempic's problem: how lost control of a blockbuster drug. 💉 Demand for GLP-1 weight-loss drugs has exploded, turning Ozempic into a $40bn+ revenue engine for Novo Nordisk. But, despite Novo Nordisk's Semaglutide Patent Expires

In an embryofetal development study in pregnant rabbits, subcutaneous doses of 0.0010, 0.0025 or 0.0075 mg/kg/day (0.03-, 0.3-, and 2.3-fold the MRHD) were administered throughout organogenesis from Gestation Day 6 to 19

Well, because I cant. With 20 years of data on using GLP-1s to treat diabetes, scientists havent identified any significant long-term complications, Kushner said

Skin Tone Improvement: Regular use may help diminish dark spots, hyperpigmentation, and other skin discolorations, leading to a more uniform complexion

Mitophagy contributes to this tumor-suppressive function by maintaining mitochondrial quality control (MQC)